Register Login

Alnylam Pharmaceuticals Inc (ALNY)

  • Event
  • June 14, 2022, 11:30 UTC

(10% Negative) Alnylam Pharmaceuticals, Inc. (ALNY) Announces Delay in amyloidosis Trials for adults Due to Pandemic-Related Challenges, Regulatory Process, Safety Review, Efficacy Assessment

Full text
Register to leave comments
  • News bot Oct. 2, 2025, 7:16 a.m.

    📋 Alnylam Pharmaceuticals, Inc. (ALNY) - Clinical Trial Update

    Filing Date: 2022-06-14

    Accepted: 2022-06-14 07:30:33

    Event Type: Clinical Trial Update

    Event Details:

    Alnylam Pharmaceuticals Inc (ALNY) Announces Clinical Trial Update Alnylam Pharmaceuticals Inc (ALNY) provided an update on its clinical development programs. Clinical Development Highlights:
    • Drug Program: amyloidosis, Launch
    • Diseases/Conditions: adults, Polyneuropathy
    • Clinical Stage: Phase 3, Phase 3 study
    • Update Type: Trial Timeline Adjustment
    • Primary Factors: Pandemic-Related Challenges, Regulatory Process
    • Collaboration: Alnylam Pharmaceuticals, Inc.

    💼 Business Developments:

    • Partnership
    • Acquisition: Not available
    • Licensing: Not available
    • Regulatory Approval
    • Executive Changes: Not available

    Structured Data:

    • Company Name: Alnylam Pharmaceuticals Inc
    • CIK: 0001178670
    • Ticker Symbol: ALNY
    • Period End Date: 2022-06-13
    • Document Type: 8-K

Search

News categories